Product Code: BIO146C
Highlights:
The global genome editing market should reach $12.8 billion by 2027 from $4.3 billion in 2022 at a compound annual growth rate (CAGR) of 24.7% for the forecast period of 2022 to 2027.
The CRISPR-Cas technology segment of the global genome editing market is expected to grow from $3.1 billion in 2022 to $9.9 billion in 2027 at a CAGR of 26.3% for the forecast period of 2022 to 2027.
The TALEN technology segment of the global genome editing market is expected to grow from $524.5 million in 2022 to $1.2 billion in 2027 at a CAGR of 18.9% for the forecast period of 2022 to 2027.
Report Scope:
This study is focused on the market side of genome editing and provides a comprehensive review of genome-editing technologies, along with updates on the latest related progress in the field. Different market segments for this specific market are covered. For example, application-based market segments include drug development, plant breeding, diagnostics, clinical therapy and other applications; and regional market segments include the U.S., Europe, Asia-Pacific and the Rest of the World.
Specifically centered on the market itself and its environment, this report covers almost all aspects of the global genome-editing industry, including its technologies, applications and markets, which are further segmented and analyzed by region, application, end user and technology. The report forecasts the sizes and trends of the global market as well as each of its segments. It details recent technical breakthroughs as well as major technical issues to overcome before genome editing is applied to clinical applications. The growth-driving factors and the factors that may limit the market's growth are identified. The ethical issues, regulatory issues and intellectual property rights issues are discussed. The trends of patent publications and research publications in the genome-editing area are analyzed. The competitive landscape, including various growth strategies and opportunities, is discussed. Comprehensive company profiles of the major players in the current genome-editing field are also included in this report. The report also includes impact of the COVID-19 pandemic on this market. For market estimates, data has been provided for the 2020 as the historic year, 2021 as the base year, and forecast for 2027.
Report Includes:
- 35 tables
- An up-to-date review of the global market for genome editing technologies and applications
- Analyses of the global market trends, with historic market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Evaluation and forecast the market size for genome editing industry, and corresponding market share analysis by technology, application, end user and geographic region
- In-depth information (facts and figures) concerning market drivers, market deterrents and other macroeconomic forces influencing the progress of this genome editing market
- A look at the recent technical breakthrough on the use of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, and how it has fuelled the rapid growth of the genome editing industry
- Identification of companies best positioned to meet this demand owing to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
- Emphasis on the recent breakthrough innovations, key technological issues, market regulations, and current status on the intellectual property rights of the CRISPR-Cas9 genome editing technology
- Review of patent trends and research publications for innovations within the global genome editing industry
- Insight into recent industry structure, current competitive scenario, R&D activities, growth strategies and COVID-19 implications on the genome editing market
- Descriptive company profiles of the leading global players, including Arbor Biotechnologies Inc., Bio-Rad Laboratories Inc., CRISPR Therapeutics, Intellia Therapeutics, Mammoth Biosciences and Thermo Fisher Scientific Inc.
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- What's New in This Update?
- Scope of Report
- Intended Audience
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- BCC Custom Research
- Related BCC Research Reports
Chapter 2 Summary and Highlights
- Highlights of the Market for Genome Editing
Chapter 3 Current Genome-Editing Technologies
- Overview
- History of Genome Editing
- Comparison of Genome Editing Technologies
- Discovery of CRISPR-Cas9
- Components of CRISPR-Cas Systems
- SgRNA
- Cas9 Nucleases
- How CRISPR-Cas Works
- Advantage of the CRISPR-Cas9 System
- Popularity of CRISPR Genome Editing
- Major Technological Issues
- Efficiency
- Specificity/Off-Target Effect
- Delivery Systems
- Immunogenicity Risk for Clinical Applications
- A New Genome-Editing System: CRISPR-Cpf1
- Studies on Treating Diseases Using Genome Editing
- Impact of Genome Editing
- Future of CRISPR
Chapter 4 Applications of Genome Editing
- Introduction
- Drug Discovery and Development
- Clinical Therapy
- Non-transgenic Breeding
- Diagnostics
- Other Applications
Chapter 5 Patents and Publication Analysis
- Patent Analysis
- Publication Analysis
Chapter 6 Market Breakdown by Technology
- Market Overview
- Market Share and Forecast
- CRISPR-Cas Technology
- TALEN
- ZFN
- Other Technologies
Chapter 7 Market Breakdown by Application
- Market Overview
- Market Share and Forecast
- Drug Development
- Plant Breeding
- Diagnostics
- Clinical Therapy
- Others
Chapter 8 Market Breakdown by End User
- Market Overview
- Market Share and Forecast
- Biotechnology and Pharmaceutical Companies
- Agricultural Biotechnology Companies
- Research Institutions
- Others
Chapter 9 Market Breakdown by Region
- Global Market for Genome Editing by Region
- United States
- Europe
- Germany
- United Kingdom
- France
- Rest of Europe
- Asia-Pacific
- China
- Australia
- Japan
- Rest of Asia-Pacific
- Rest of the World
Chapter 10 Competitive Landscape
- Overview
- Growth Strategies
- Licensing and Agreements
- Collaborations with Big Biopharmaceutical Companies
- In-House R&D Program
- Mergers and Acquisitions
- Venture Capital Funding
Chapter 11 Factors Influencing the Genome Editing Market
- Driving Forces
- New Genome-Editing Technologies and Applications
- Need for Precision Medicine
- Increasing Applications in Synthetic Biology and Drug Discovery
- Investments from Both Public and Private Sectors
- High Prevalence of Genetic Disorders
- Applications in Plant and Livestock Breeding
- Factors Limiting Market Growth
- Stringent Regulatory Frameworks and Time-Consuming Approval Processes
- Patent Disputes
- Governmental Policies and Regulations
- Regulatory Uncertainty on Genome-Edited Crops
- Ethical Issues
Chapter 12 Impact of COVID-19 on the Genome Editing Market
Chapter 13 Company Profiles
- ALDEVRON
- ALLELE BIOTECHNOLOGY
- AMERICAN TYPE CULTURE COLLECTION (ATCC)
- APPLIED STEMCELL INC.
- ARBOR BIOTECHNOLOGIES INC.
- ATUM (DNA2.0)
- AUSTRALIAN BIORESOURCES LTD.
- AXOL BIOSCIENCE LTD.
- BEAM THERAPEUTICS
- BIOCYTOGEN
- BIO-RAD LABORATORIES INC.
- BIOTOOLS CO. LTD.
- BLUEBIRD BIO
- BIO-TECHNE
- CALYXT INC.
- CANOPY BIOSCIENCES
- CARIBOU BIOSCIENCES INC.
- CRISPR THERAPEUTICS
- EDITAS MEDICINE
- GENECOPOEIA
- GENEWIZ
- GENSCRIPT
- HERA BIOLABS
- HORIZON DISCOVERY
- INTELLIA THERAPEUTICS INC.
- INTEGRATED DNA TECHNOLOGIES
- JUNO THERAPEUTICS
- LONZA
- MAMMOTH BIOSCIENCES
- MERCK KGAA (SIGMA-ALDRICH)
- ORIGENE TECHNOLOGIES
- PRECISION BIOSCIENCES INC.
- RECOMBINETICS
- REGENERON PHARMACEUTALS INC.
- SANGAMO BIOSCIENCES
- SYNTHEGO
- SYSTEM BIOSCIENCES
- TAKARA BIO USA INC.
- THERMO FISHER SCIENTIFIC INC.
- TOOLGEN INC.
- VERTEX PHARMACEUTICALS INC.